Brief: Arovella Therapeutics Gives ALA-101 And Oncarlytics Collaboration Update

Imugene

20/03/2024 01:33

March 20 (Reuters) - Arovella Therapeutics Ltd  ALA.AX :
    * ALA-101 AND ONCARLYTICS COLLABORATION UPDATE
    * IMUGENE HAS ADVISED AROVELLA THAT IT NO LONGER WISHES TO
CONTINUE COLLABORATION
    * PARTNERSHIP TO COMBINE ALA‐101 AND ONCARLYTICS HAS ENDED
    * NO FINANCIAL IMPACT FROM CESSATION OF COLLABORATION FOR
AROVELLA
    * COLLABORATION WILL BE TERMINATED WITH IMMEDIATE EFFECT
    * TERMINATION WILL NOT IMPACT CO'S DEVELOPMENT OF ALA‐101
FOR
CD19‐POSITIVE BLOOD CANCERS

Further company coverage:  ALA.AX 

 ((Reuters.Briefs@thomsonreuters.com;;))